Our latest articles
The mid-stage Nash pipeline plays host to mechanisms both evidence-backed and unproven, with plenty of data on the horizon.
Biogen’s acquisition of rare neurological disease player Reata provides a much needed near-term sales lift, but at a price.
But supply problems are getting worse.
Catalysts from several late-stage projects including those from Astrazeneca, Sanofi, Allakos and Celldex aim to shake up the market.
With a focus on France and Germany, the company builder is also closing in on its final two targets.
But how different is ACU193 really?
But subgroup analyses from Trailblazer-Alz 2 show that earlier is better for donanemab.
The latest deal focuses on in vivo Crispr editing for sickle cell disease, and follows last year’s cancer collaboration.
The Belgian group is riding high as investors look for future successes in other inflammatory diseases.
A convincing hit puts approval, and potentially partnerships, on the table.